End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
7,75,000 KRW | +0.65% | -3.37% | +1.97% |
25/04 | Samsung Bioepis Granted Approval to Market Autoimmune Treatment in Europe | MT |
25/04 | Samsung Biologics Posts Higher Q1 Profit, Sales | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 51% by 2026.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 56.66 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.97% | 40.1B | A- | ||
-3.45% | 87.17B | A- | ||
+57.92% | 25.12B | A | ||
-14.82% | 15.59B | C | ||
-8.82% | 12B | D+ | ||
-16.29% | 11.8B | B- | ||
-41.58% | 11.8B | B | ||
+6.89% | 8.81B | B+ | ||
-10.53% | 8.24B | B- | ||
+0.95% | 7.62B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- A207940 Stock
- Ratings Samsung Biologics Co.,Ltd.